# Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

> **NCT03930771** · PHASE2 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 1 (actual)

## Conditions studied

- Recurrent Pituitary Adenomas

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT03930771
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-21
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-10-01
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** the study had a low accrual rate
- **Last updated:** 2022-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03930771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03930771, "Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03930771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*